Journal of Pediatric Hematology/Oncology最新文献_第10页

Nivolumab-associated IgA Nephropathy in a Child With Malignant Melanoma. 一名恶性黑色素瘤患儿的 Nivolumab 相关 IgA 肾病。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-07-25 DOI: 10.1097/MPH.0000000000002931

Gizem Yildiz, Meral Torun Bayram, Şadiye Mehtat Ünlü, Alper Soylu, Salih Kavukçu, Nur Olgun

引用次数: 0

Late Relapse in Genetically Determined Infantile Myofibromatosis. A Case Report and Brief Focus on Recurrences. 基因决定性婴幼儿肌纤维瘤病的晚期复发。病例报告和复发简析。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-14 DOI: 10.1097/MPH.0000000000002942

Alessio Conte, Damiana De Padova, Serena Giglio, Virginia Livellara, Carla Manzitti, Patrizia De Marco, Valeria Capra, Stefania Sorrentino

引用次数: 0

Givosiran for the Treatment of Pediatric Acute Intermittent Porphyria. 治疗小儿急性间歇性卟啉症的吉沃西兰。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-22 DOI: 10.1097/MPH.0000000000002941

Kenneth E Bujold, Nicole Kasher, Christine McKiernan

引用次数: 0

Central Venous Catheter-associated Venous Thromboembolism in Children: A Prospective Observational Study. 儿童中心静脉导管相关静脉血栓栓塞症：前瞻性观察研究

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-07-22 DOI: 10.1097/MPH.0000000000002923

Aditya S Narayan, Jaikumar Govindaswamy Ramamoorthy, Narayanan Parameswaran, G RamKumar, Smita Kayal

{"title":"Central Venous Catheter-associated Venous Thromboembolism in Children: A Prospective Observational Study.","authors":"Aditya S Narayan, Jaikumar Govindaswamy Ramamoorthy, Narayanan Parameswaran, G RamKumar, Smita Kayal","doi":"10.1097/MPH.0000000000002923","DOIUrl":"10.1097/MPH.0000000000002923","url":null,"abstract":"Our objective was to study the proportion of children developing Catheter-related thrombosis (CRT) following central venous Catheter (CVC) insertion and the risk factors of CRT in pediatric patients with CVC. One hundred four children aged 29 days to 18 years who had a percutaneous non-tunneled CVC inserted were enrolled. Ultrasonogram (USG) with venous Doppler scan was performed within 48 hours of CVC removal to diagnose CRT. The major indications for CVC insertion were surgical care 34 (32.6%) and ICU care 28(26.9%). The median age of the patients was 3 years, and 75% were males. The median number of CVC days was 10 (IQR 5.15). CRT was seen in 45(43.3%), of which 33 (73.3%) were asymptomatic. The rate of CRT was 35.69 cases per 1000 CVC days (95% CI 26.03-47.75). The number of days a catheter was in place and USG-guided catheter insertion was a significant risk factor. The multivariate logistic regression model showed that the duration of CVC in situ was independently associated with the development of CRT (OR, 1.06; 95% CI 1.0-1.1; P =0.02). CVC duration was a major risk factor for the development of CRT. There was a higher risk of developing a symptomatic CRT with central venous catheters than hemodialysis sheaths.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e544-e549"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141759320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers in Pediatric Hemophagocytic Lymphohistiocytosis With Central Nervous System Involvement: A Cohort Study. 中枢神经系统受累的小儿嗜血细胞淋巴组织细胞增多症的生物标志物：队列研究

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-15 DOI: 10.1097/MPH.0000000000002937

Yunze Zhao, Wenxin Ou, Ang Wei, Honghao Ma, Liping Zhang, Hongyun Lian, Qing Zhang, Dong Wang, Zhigang Li, Rui Zhang, Tianyou Wang

{"title":"Biomarkers in Pediatric Hemophagocytic Lymphohistiocytosis With Central Nervous System Involvement: A Cohort Study.","authors":"Yunze Zhao, Wenxin Ou, Ang Wei, Honghao Ma, Liping Zhang, Hongyun Lian, Qing Zhang, Dong Wang, Zhigang Li, Rui Zhang, Tianyou Wang","doi":"10.1097/MPH.0000000000002937","DOIUrl":"10.1097/MPH.0000000000002937","url":null,"abstract":"Background: The aim of this study was to analyze the clinical significance of cerebrospinal fluid (CSF) cytokines in hemophagocytic lymphohistiocytosis associated with central nervous system (CNS-HLH).Methods: CSF cytokine levels, including interferon (IFN)-γ, soluble CD25 (sCD25), interleukin (IL)-6, IL-10, IL-18, and CXCL9 were measured at disease onset and during the treatment. Five newly diagnosed patients with demyelination disease were enrolled for comparison.Results: Sixty-five samples from 36 patients (13 in the CNS group and 23 in the non-CNS group) were detected. Levels of CSF IFN-γ, sCD25, IL-10, IL-18, and CXCL9 in the CNS group were higher than those in the non-CNS group ( P =0.038, <0.001, <0.001, 0.005, and <0.001), and levels of CSF sCD25, IL-10, IL-18, and CXCL9 in the CNS group were higher than those in the demyelination group ( P =0.001, 0.008, 0.004, and 0.003). There was no significant difference in IL-6 levels among the 3 groups ( P =0.339). CSF IFN-γ, sCD25, IL-10, IL-18, and CXCL9 could assist in diagnosing CNS-HLH. The diagnostic efficiency of CSF sCD25, IL-10, and CXCL9 was better, with a cutoff value of 154.64, 1.655, and 19.54 pg/mL, respectively. The area under the curve was >0.9, with sensitivity and specificity >80%. Correlation analysis suggested that in the CNS group, IFN-γ levels in CSF and serum correlated positively ( R =0.459, P =0.007), while there was no correlation between CSF CXCL9 and serum IFN-γ ( P =0.915).Conclusions: CSF IFN-γ, sCD25, IL-10, IL-18, and CXCL9 levels were significantly higher in HLH patients with CNS involvement than those without and could predict HLH patients with CNS involvement. CSF CXCL9 might be a more sensitive biomarker to CNS-HLH than IFN-γ, while CSF IL-6 does not seem to play a vital role.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"364-372"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patterns of Growth of Tumors in Li-Fraumeni Syndrome by Imaging: A Case Series. 李-弗劳米尼综合征肿瘤的影像学生长模式：病例系列。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-26 DOI: 10.1097/MPH.0000000000002928

Roxana Azma, Jesus Arenos-Abril, Thitiporn Junhasavasdiku, Nipaporn Tewattanarat, Armin Nourmohammad, Armin Abadeh, Sanuj Panwar, Anita Villani, David Malkin, Andrea S Doria

{"title":"Patterns of Growth of Tumors in Li-Fraumeni Syndrome by Imaging: A Case Series.","authors":"Roxana Azma, Jesus Arenos-Abril, Thitiporn Junhasavasdiku, Nipaporn Tewattanarat, Armin Nourmohammad, Armin Abadeh, Sanuj Panwar, Anita Villani, David Malkin, Andrea S Doria","doi":"10.1097/MPH.0000000000002928","DOIUrl":"10.1097/MPH.0000000000002928","url":null,"abstract":"Although tumors of Li-Fraumeni syndrome (LFS) have a premalignant or dormant phase that could be exploited by early imaging detection, this has been underevaluated in the literature. We present a case series of patients with LFS followed by imaging over time to highlight patterns of growth of tumors and hotspots of missed tumors in this population. Clinical and imaging features were available for 29 tumors of 24 carriers of a germline TP53 pathogenic variant, developed between 1999 and 2023 were retrospectively reviewed in a single tertiary pediatric center. Imaging characteristics of tumors were evaluated with MRI, CT, and radiographs. Local invasion, time interval for developing primary cancer, and/or recurrent disease and metastasis, and factors that delayed the tumor diagnosis were assessed. In patients with multiple tumors the median time intervals for development of first, second, and third primary cancers were 45.9, 79.8, and 28.1 months, respectively. Hotspots of missed tumors included superficial soft tissues, areas close to bones, on the scalp, in tissues around the adrenal region and in small hypodense lesions on brain CT. In conclusion, the pattern of growth of tumors is variable and erratic in LFS patients with some tumors presenting with a dormant pattern.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"335-348"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Hemorrhagic Brain Mass in a Child With Encephalocraniocutaneous Lipomatosis. 脑颅皮肤脂肪瘤病患儿的出血性脑肿块

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-27 DOI: 10.1097/MPH.0000000000002947

Erin Hall, Francisco A Perez, Bonnie Cole, Vera Paulson, Sarah Leary, Rebecca Ronsley

引用次数: 0

Primary Central Nervous System Burkitt's Lymphoma in a Pediatric Patient: A Case Report and Literature Review. 一名儿童患者的原发性中枢神经系统伯基特淋巴瘤：病例报告与文献综述。

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-09-26 DOI: 10.1097/MPH.0000000000002944

Jian Zhao, Mohammad Arian Hassani, Jincheng Song, Xiuhua Sun

{"title":"Primary Central Nervous System Burkitt's Lymphoma in a Pediatric Patient: A Case Report and Literature Review.","authors":"Jian Zhao, Mohammad Arian Hassani, Jincheng Song, Xiuhua Sun","doi":"10.1097/MPH.0000000000002944","DOIUrl":"10.1097/MPH.0000000000002944","url":null,"abstract":"Objective: The objective of this research is to examine the therapy and outlook of pediatric primary central nervous system Burkitt lymphomas.Methods: This study involves a retrospective analysis of the clinical data of a child with primary central nervous system Burkitt lymphoma who underwent treatment in our department. In addition, pertinent literature was reviewed to provide a comprehensive understanding of the topic.Results: The patient was admitted to the neurosurgery department with symptoms of headache and vomiting. Brain magnetic resonance imaging (MRI) revealed multiple lesions in the right frontal and temporal lobes, dorsal thalamus, and posterior medulla oblongata. Most of the tumor mass was surgically removed from the right ventricle and diagnosed as Burkitt lymphoma. Abnormal lymph nodes were not found outside of the central nervous system. The patient achieved complete remission (CR) after receiving 6 cycles of treatment (R-AA-BB-CC-AA-BB-CC) based on the regimen of the Southern Pediatric Non-Hodgkin Lymphoma Treatment Collaboration Group 2017. As of November 23, 2023, the patient remained alive with no evidence of recurrence.Conclusions: Primary central nervous system Burkitt lymphoma is rare in children, and there is no universally accepted treatment protocol. However, the regimen outlined by the South China Children's Cancer Group-Non-Hodgkin Lymphoma in 2017 (SCCCG-NHL-2017) can serve as a useful reference for treating pediatric non-Hodgkin lymphoma.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":"46 7","pages":"375-379"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142348707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PET/CT Response Assessment in Pediatric Hodgkin Lymphoma: Does Deauville Score 3 Reflect Negativity? PET/CT 对小儿霍奇金淋巴瘤的反应评估：多维尔评分 3 是否反映了阴性？

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-22 DOI: 10.1097/MPH.0000000000002943

Samah Semary, Emad Moussa, Maram Salama, Mona Fakhry, Asmaa Attia, Maha Mehesen, Eman Khorshed, Madeeha Elwekeel, Amr Elnashar, Mohamed Sedky, Asmaa Hamoda

{"title":"PET/CT Response Assessment in Pediatric Hodgkin Lymphoma: Does Deauville Score 3 Reflect Negativity?","authors":"Samah Semary, Emad Moussa, Maram Salama, Mona Fakhry, Asmaa Attia, Maha Mehesen, Eman Khorshed, Madeeha Elwekeel, Amr Elnashar, Mohamed Sedky, Asmaa Hamoda","doi":"10.1097/MPH.0000000000002943","DOIUrl":"10.1097/MPH.0000000000002943","url":null,"abstract":"Background: FDG PET is required for the staging and response evaluation of pediatric Hodgkin lymphoma. This study aimed to evaluate the outcomes of pediatric patients with Hodgkin's lymphoma based on interim PET CT assessments of early response following second-cycle chemotherapy using the Deauville score (DS). It also determines whether DS-3 is providing an adequate or inadequate response.Methods: We conducted a retrospective cohort study including 504 pediatric patients with classic Hodgkin lymphoma who were treated with chemotherapy based on the Euro-Net protocol at the Children Cancer Hospital Egypt from March 2019 till the end of October 2022.Results: Patients with adequate response DS 1/2 and DS 3 showed nearly the same 3-year event-free survival (EFS) of 91.9% and 91.5%, respectively, compared with those patients with inadequate response DS 4/5, who showed an EFS of 80.4% ( P =0.001). Patients with a DS 3 at interim PET evaluation were considered negative as DS 1/2. Patients of DS 3 group who did not receive radiotherapy had a much worse 3-year EFS by the existence of positive B symptoms, an ESR>30, or an advanced stage. Radiation therapy did not improve the 3-year EFS in patients with an inadequate response (DS4/5) and poor prognostic characteristics. They still need more advanced treatment.Conclusion: DS 1/2 and DS 3 had about the same 3-year EFS, which is better than the 3-year EFS of patients with DS 4/5. Therefore, we can classify DS 3 as having negative FDG PET CT uptake.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":"e493-e500"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Pediatric Case of B Cell Precursor ALL With Blinatumomab-associated Encephalopathy. 一例B细胞前体ALL合并Blinatumomab相关脑病的儿科病例

IF 0.9 4区医学

Journal of Pediatric Hematology/Oncology Pub Date : 2024-10-01 Epub Date: 2024-07-15 DOI: 10.1097/MPH.0000000000002925

Maiko Shimomura, Mari Tanaka, Yoshiyuki Kobayashi, Hiroki Izumo, Yuichi Tateishi, Yoko Mizoguchi, Hiroshi Kawaguchi, Satoshi Okada, Shuhei Karakawa

引用次数: 0